- Nachrichtendetail
-
09.07.2024 03:17:54 - dpa-AFX: Moderna, Mitsubishi Tanabe To Co-Promote MRNA Respiratory Vaccines In Japan, Incl. COVID-19 Vaccine
WASHINGTON (dpa-AFX) - Moderna Inc. (MRNA) and Mitsubishi Tanabe Pharma
Corporation have partnered to jointly promote Moderna's mRNA respiratory vaccine
portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax.
As per the agreement, Moderna will handle the manufacturing, sales, medical
education and distribution of its mRNA respiratory vaccines. The companies will
engage in activities to enable broad access to Moderna's mRNA respiratory
portfolio to have the maximum impact on public health in Japan.
The agreement has an initial term until March 31, 2029 and no further details on
the financial terms of the deal are being disclosed.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Corporation have partnered to jointly promote Moderna's mRNA respiratory vaccine
portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax.
As per the agreement, Moderna will handle the manufacturing, sales, medical
education and distribution of its mRNA respiratory vaccines. The companies will
engage in activities to enable broad access to Moderna's mRNA respiratory
portfolio to have the maximum impact on public health in Japan.
The agreement has an initial term until March 31, 2029 and no further details on
the financial terms of the deal are being disclosed.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
MODERNA INC. DL-,0001 | A2N9D9 | Xetra | 111,580 | 22.07.24 11:42:40 | +1,320 | +1,20% | 111,440 | 111,940 | 111,440 | 110,260 |
